Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Assets Average (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Assets Average for 8 consecutive years, with $173.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 85.69% to $173.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $173.9 million, a 85.69% increase, with the full-year FY2024 number at $101.4 million, down 35.97% from a year prior.
  • Assets Average was $173.9 million for Q3 2025 at Whitehawk Therapeutics, down from $207.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $207.4 million in Q2 2025 to a low of $39.3 million in Q2 2021.
  • A 5-year average of $133.7 million and a median of $145.4 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 244.79% in 2022, then tumbled 42.66% in 2024.
  • Whitehawk Therapeutics' Assets Average stood at $163.3 million in 2021, then increased by 15.81% to $189.2 million in 2022, then fell by 28.09% to $136.0 million in 2023, then tumbled by 42.66% to $78.0 million in 2024, then skyrocketed by 122.95% to $173.9 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Assets Average are $173.9 million (Q3 2025), $207.4 million (Q2 2025), and $152.2 million (Q1 2025).